Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit
Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit
复制标题
DOI：
10.1076/ceyr.22.6.451.5486
复制
发表时间：
2001-06-01
影响因子：
2
通讯作者：
O'Callaghan, RJ
中科院分区：
文献类型：
--
作者：
Dajcs, JJ;Thibodeaux, BA;O'Callaghan, RJ
目的.目的探讨溶葡萄球菌酶对耐甲氧西林金黄色葡萄球菌（MRSA）所致实验性眼内炎的治疗作用。在一个实验中，将50或200 CFU的S.金黄色;未处理组和在感染后8或24小时玻璃体内注射载体或溶葡萄球菌酶（0.1mg/ml）的组在感染后24或48小时的CFU/ml玻璃体方面进行比较。还比较了未治疗和治疗眼的组织学。为了定量溶葡萄球菌酶的效力，给另外的兔子注射50 CFU的S.在感染后24小时，根据CFU/ml玻璃体比较金黄色葡萄球菌和未处理的眼睛以及在8小时用0.001、0.01或0.05 mg/ml处理的眼睛。用50或200 CFU S.感染后24或48小时，金黄色葡萄球菌中含有500 - 1000万CFU/ml。所有用溶葡萄球菌酶处理的眼睛在感染后8小时在玻璃体中具有小于1 log CFU/ml（P小于或等于0.0001）。类似地，在感染后24小时用溶葡萄球菌酶处理的眼睛在感染后48小时具有约llog CFU/ml。未处理的眼睛均无菌，感染后8或24小时分别有88%或50%的眼睛无菌。在感染后8小时而不是24小时，用溶葡萄球菌酶治疗的眼睛比未治疗的眼睛有较不明显的病理变化（P = 0.002）。在感染后8小时用浓度大于或等于0.001 mg/ml的溶葡萄球菌酶处理感染眼，感染后24小时玻璃体CFU/ml显著降低（P小于或等于5 0.0034）。溶葡萄球菌酶对MRSA介导的实验性眼内炎有较好的治疗作用。
Purpose. To determine the effectiveness of lysostaphin treatment of experimental endophthalmitis caused by methicillin-resistant Staphylococcus aureus (MRSA).Methods. In one experiment, rabbits were injected in the mid-vitreous with 50 or 200 CFU of S. aureus; untreated groups and groups injected intra-vitreally at 8 or 24 hours postinfection with vehicle or lysostaphin (0.1 mg/ml) were compared in terms of CFU/ml vitreous at 24 or 48 hours postinfection. Histopathology of untreated and treated eyes was also compared. To quantify the potency of lysostaphin, additional rabbits were injected with 50 CFU of S. aureus and untreated eyes and eyes treated at 8 hours with 0.001, 0.01 or 0.05 mg/ml were compared in terms of CFU/ml vitreous at 24 hours postinfection.Results. Vitreous of untreated eyes or vehicle-treated eyes injected with 50 or 200 CFU of S. aureus contained 5-10 million CFU/ml at 24 or 48 hours postinfection. All eyes treated with lysostaphin at 8 hours postinfection had less than 1 log CFU/ml in the vitreous (P less than or equal to 0.0001). Similarly, eyes treated with lysostaphin at 24 hours postinfection had approximately 1 log of CFU/ml at 48 hours postinfection. None of the untreated eyes were sterile and 88% or 50% of the eyes treated at 8 or 24 hours postinfection, respectively, were sterile. Eyes treated with lysostaphin at 8, but not 24, hours postinfection had less pronounced pathologic changes than the untreated eyes (P = 0.002). A significant reduction in the CFU/ml vitreous at 24 hours postinfection was obtained by treating infected eyes at 8 hours postinfection with lysostaphin at concentrations of greater than or equal to0.001 mg/ml (P less than or equal to5 0.0034).Conclusions. Lysostaphin is effective in treating experimental endophthalmitis mediated by MRSA.